Evidence map›Paper›PMID 31379512›Full record

ReviewFrontiers in cellular neuroscience2019

TMP21 in Alzheimer's Disease: Molecular Mechanisms and a Potential Target.

Kaixin Qiu, Xiaojie Zhang, Shuai Wang, Chunyan Li, Xin Wang, Xuezhi Li, Yili Wu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cellular neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Orexinergic System in Neurodegenerative Diseases.Frontiers in aging neuroscience · 2021
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kaixin QiuCheeloo College of Medicine, Shandong University, Jinan, China.
Xiaojie ZhangDepartment of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China.
Shuai WangShandong Collaborative Innovation Center for Diagnosis, Treatment and Behavioral Interventions, Institute of Mental Health, Jining Medical University, Jining, China.
Chunyan LiCheeloo College of Medicine, Shandong University, Jinan, China.
Xin WangShandong Collaborative Innovation Center for Diagnosis, Treatment and Behavioral Interventions, Institute of Mental Health, Jining Medical University, Jining, China.
Xuezhi LiShandong Collaborative Innovation Center for Diagnosis, Treatment and Behavioral Interventions, Institute of Mental Health, Jining Medical University, Jining, China.
Yili WuShandong Collaborative Innovation Center for Diagnosis, Treatment and Behavioral Interventions, Institute of Mental Health, Jining Medical University, Jining, China.
Jining Medical University · CNCentral South University · CNShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common form of dementia in the elderly, which is characterized by progressive cognitive impairment. Neuritic plaques, neurofibrillary tangles and neuronal loss are the major neuropathological hallmarks in AD brains. TMP21 is a key molecule for protein trafficking in cells. Growing evidence indicates that TMP21 is dysregulated in AD, which plays a pivotal role in neuritic plaque formation. Therefore, we aim to review the dysregulation of TMP21 in AD, the role of TMP21 in neuritic plaque formation and underlying mechanisms. Moreover, the potential role of TMP21 in neurofibrillary tangle formation, synaptic impairment and neuronal loss is discussed. It will provide an outlook into the potential of regulating TMP21 as a therapeutic approach for AD treatment.

Indexed as

Alzheimer’s diseaseAβneuronal lossTau phosphorylationTMP21

Identifiers

PMID31379512
PMCPMC6651510
OpenAlexW2959659969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.